Clinical characterisation of Becker muscular dystrophy patients predicts favourable outcome in exon-skipping therapy

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 85, Issue 1, 2014, Pages 92-98

  Van Den Bergen, J C ^a   Van Westrum, S M Schade ^b,c   Dekker, L ^d   Van Der Kooi, A J ^b   De Visser, M ^b   Wokke, B H A ^a   Straathof, C S ^a   Hulsker, M A ^a   Aartsma Rus, A ^a   Verschuuren, J J ^a   Ginjaar, H B ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c MARTINI HOSPITAL   (Netherlands)

^d Catharina Medical Center   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; ASSISTED VENTILATION; BECKER MUSCULAR DYSTROPHY; CHILD; CLINICAL FEATURE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DMD GENE; EDUCATIONAL STATUS; EXON SKIPPING; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUSCLE BIOPSY; MUTATOR GENE; OUTCOME ASSESSMENT; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL;

EID: 84891829592     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2012-304729     Document Type: Article

References (36)

1. Koenig M, Hoffman EP, Bertelson CJ, et al. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 1987;50: 509-17. (Pubitemid 18098338)
2. Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol 2003;2: 731-40. (Pubitemid 37443515)
3. Kohler M, Clarenbach CF, Bahler C, et al. Disability and survival in Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry 2009;80: 320-5.
4. Ishikawa Y, Miura T, Ishikawa Y, et al. Duchenne muscular dystrophy: survival by cardio-respiratory interventions. Neuromuscul Disord 2011;21: 47-51.
5. Bach JR, Martinez D. Duchenne muscular dystrophy: continuous noninvasive ventilatory support prolongs survival. Respir Care 2011;56: 744-50.
6. Angelini C, Fanin M, Pegoraro E, et al. Clinical-molecular correlation in 104 mild X-linked muscular dystrophy patients: characterization of sub-clinical phenotypes. Neuromuscul Disord 1994;4: 349-58. (Pubitemid 24280932)
7. Bushby KM, Gardner-Medwin D. The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. I. Natural history. J Neurol 1993;240: 98-104. (Pubitemid 23073200)
8. Beggs AH, Hoffman EP, Snyder JR, et al. Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. Am J Hum Genet 1991;49: 54-67. (Pubitemid 21891653)
9. Bushby KM, Gardner-Medwin D, Nicholson LV, et al. The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. II. Correlation of phenotype with genetic and protein abnormalities. J Neurol 1993;240: 105-12. (Pubitemid 23073201)
10. Comi GP, Prelle A, Bresolin N, et al. Clinical variability in Becker muscular dystrophy. Genetic, biochemical and immunohistochemical correlates. Brain 1994;117: 1-14. (Pubitemid 24103380)
11. Aartsma-Rus A, Fokkema I, Verschuuren J, et al. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 2009;30: 293-9.
12. van Ommen GJ, van DJ, Aartsma-Rus A. The therapeutic potential of antisense-mediated exon skipping. Curr Opin Mol Ther 2008;10: 140-9. (Pubitemid 351498876)
13. Aartsma-Rus A, van, Ommen GJ. Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. RNA 2007;13: 1609-24. (Pubitemid 47481669)
14. Schade van Westrum SM, Hoogerwaard EM, Dekker L, et al. Cardiac abnormalities in a follow-up study on carriers of Duchenne and Becker muscular dystrophy. Neurology 2011;77: 62-6.
15. Henry WL, Gardin JM, Ware JH. Echocardiographic measurements in normal subjects from infancy to old age. Circulation 1980;62: 1054-61. (Pubitemid 11225973)
16. WHO/ISFC task force. Report of the WHO/ISFC task force on the definition and classification of cardiomyopathies. Br Heart J 1980;44: 672-3.
17. van Deutekom JC, Janson AA, Ginjaar IB, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 2007;357: 2677-86.
18. Aartsma-Rus A, Janson AA, Kaman WE, et al. Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum Mol Genet 2003;12: 907-14. (Pubitemid 36504033)
19. Anthony K, Cirak S, Torelli S, et al. Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials. Brain 2011;134: 3547-59.
20. Helderman-van den Enden AT, Straathof CS, Aartsma-Rus A, et al. Becker muscular dystrophy patients with deletions around exon 51; a promising outlook for exon skipping therapy in Duchenne patients. Neuromuscul Disord 2010;20: 251-4.
21. Emery A, Muntoni F. Duchenne muscular dystrophy. 3rd edn. Oxford: Oxford University Press, 2005.
22. de Visser M, de Voogt WG, la Riviere GV. The heart in Becker muscular dystrophy, facioscapulohumeral dystrophy, and Bethlem myopathy. Muscle Nerve 1992;15: 591-6.
23. Saito M, Kawai H, Akaike M, et al. Cardiac dysfunction with Becker muscular dystrophy. Am Heart J 1996;132: 642-7. (Pubitemid 26347771)
24. Steare SE, Dubowitz V, Benatar A. Subclinical cardiomyopathy in Becker muscular dystrophy. Br Heart J 1992;68: 304-8.
25. Yilmaz A, Gdynia HJ, Baccouche H, et al. Cardiac involvement in patients with Becker muscular dystrophy: new diagnostic and pathophysiological insights by a CMR approach. J Cardiovasc Magn Reson 2008;10:50.
26. Nigro G, Comi LI, Politano L, et al. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol 1990;26: 271-7. (Pubitemid 20061348)
27. Heemskerk H, de Winter C, van Kuik P, et al. Preclinical PK and PD studies on 20-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model. Mol Ther 2010;18: 1210-17.
28. Heemskerk HA, de Winter CL, de Kimpe SJ, et al. In vivo comparison of 20-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J Gene Med 2009;11: 257-66.
29. Wu B, Lu P, Benrashid E, et al. Dose-dependent restoration of dystrophin expression in cardiac muscle of dystrophic mice by systemically delivered morpholino. Gene Ther 2010;17: 132-40.
30. Spitali P, Aartsma-Rus A. Splice modulating therapies for human disease. Cell 2012;148: 1085-8.
31. Cotton S, Voudouris NJ, Greenwood KM. Intelligence and Duchenne muscular dystrophy: full-scale, verbal, and performance intelligence quotients. Dev Med Child Neurol 2001;43: 497-501. (Pubitemid 32651798)
32. Dallerac G, Perronnet C, Chagneau C, et al. Rescue of a dystrophin-like protein by exon skipping normalizes synaptic plasticity in the hippocampus of the mdx mouse. Neurobiol Dis 2011;43: 635-41.
33. Sekiguchi M, Zushida K, Yoshida M, et al. A deficit of brain dystrophin impairs specific amygdala GABAergic transmission and enhances defensive behaviour in mice. Brain 2009;132: 124-35.
34. Karagan NJ, Sorensen JP. Intellectual functioning in non-Duchenne muscular dystrophy. Neurology 1981;31: 448-52. (Pubitemid 11151083)
35. Hendriksen JG, Vles JS. Neuropsychiatric disorders in males with duchenne muscular dystrophy: frequency rate of attention-deficit hyperactivity disorder (ADHD), autism spectrum disorder, and obsessive - compulsive disorder. J Child Neurol 2008;23: 477-81. (Pubitemid 351566858)
36. Mohamed K, Appleton R, Nicolaides P. Delayed diagnosis of Duchenne muscular dystrophy. Eur J Paediatr Neurol 2000;4: 219-23.